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Abstract
Background: As patients with chronic kidney disease become older, there is greater 
need to identify who will most benefit from kidney transplantation. Analytic morpho-
mics has emerged as an objective risk assessment tool distinct from chronologic age. 
We hypothesize that morphometric age is a significant predictor of survival following 
transplantation.
Methods: A retrospective cohort of 158 kidney transplant patients from 2005 to 2014 
with 1- year preoperative imaging was identified. Based on a control population com-
prising of trauma patients and kidney donors, morphometric age was calculated using 
the validated characteristics of psoas area, psoas density, and abdominal aortic calcifi-
cation. The primary outcome was post- transplant survival.
Results: Cox regression showed morphometric age was a significant predictor of sur-
vival (hazard ratio, 1.06 per morphometric year [95% confidence interval, 1.03- 1.08]; 
P < .001). Chronological age was not significant (hazard ratio, 1.03 per year [0.98- 1.07]; 
P = .22). Among the chronologically oldest patients, those with younger morphometric 
age had greater survival rates compared to those with older morphometric age.
Conclusions: Morphometric age predicts survival following kidney transplantation. 
Particularly for older patients, it offers improved risk stratification compared to chron-
ologic age. Morphomics may improve the transplant selection process and provide a 
greater assessment of prospective survival benefits.
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1  | INTRODUCTION
The determination of which patients are suitable for transplant candi-
dacy has always been a challenging task for clinicians. Transplant com-
mittees often rely on subjective physician assessments, collectively 
referred to as the “eyeball test,” to formulate a patient’s perioperative 
risk and long- term term survival.1-4 Patient age is one of the most crit-
ical factors of this assessment, but age itself can be a poor proxy for 
physiologic reserve—especially within the context of chronic kidney 
disease (CKD) and end- stage renal disease (ESRD), as well as other de-
bilitating comorbidities.5-9 As the CKD population becomes older, bet-
ter objective measures of preoperative risk are needed to distinguish 
older patients with potentially greater survival benefit than predicted 
based on chronological age alone.
Recently, our group has attempted to objectively measure this 
assessment using morphometric measurements found on cross- 
sectional imaging in different types of surgical patients.10-12 By stan-
dardizing the baseline morphometric characteristics of aging in the 
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general population, namely living kidney donors and trauma patients, 
a morphometric age was quantified to reflect these changes and found 
to be a distinct surgical risk factor from chronologic age. Thus far, mor-
phometric age has been shown to correlate to outcomes in both the 
general surgical and liver transplantation populations.13,14 We aim to 
apply these findings to the kidney transplant recipients. Many trans-
plant centers obtain abdominopelvic or pelvic computed tomography 
(CT) scans already for various indications, but most frequently for as-
sessment of vascular targets for kidney engraftment. These scans have 
additional information that can be brought out with morphomic anal-
ysis, suggesting that this approach could have minimal cost impact. 
With increased focus on clinical outcomes and resource utilization, 
optimizing patient and graft outcomes, coupled with avoiding futile 
transplants, is vital.15
As the population of those with ESRD seeking renal transplant 
has become older, differentiating between the elderly patient with 
the physiological reserve to do reasonably well with the transplant 
operation and recovery, vs those too frail to do well, has become a 
progressively important focus for transplant centers. In this study, we 
sought to determine the relationship between morphometric age as 
an indicator of frailty and post- kidney transplant survival. We hypoth-
esize that increased morphometric age will significantly correlate with 
poorer outcomes.
2  | MATERIALS AND METHODS
2.1 | Study population
This study was reviewed and approved by the Institutional 
Review Boards of both the University Hospitals Case Medical 
Center (UHCMC, IRB #07- 13- 31) and the University of Michigan 
(UMHS, IRB #HUM00041441). This study was a retrospec-
tive examination of patients who underwent kidney transplan-
tation at UHCMC between January 2005 and May 2014, and 
who had a CT scan in the year prior to transplant. At UHCMC, 
abdominopelvic or pelvic CT scans were ordered annually (per 
clinical protocol) for kidney transplant candidates who met the 
following	criteria:	age	≥50	years,	diabetes,	significant	cardiovas-
cular risk, or previous transplant. Scans were obtained in these 
patients for operative planning to assess for iliac artery calcifi-
cations and potential anastomotic targets. We also included CT 
scans ordered for other clinical indications, as long as they were 
within 1 year pre- transplant. In patients with multiple pretrans-
plant CT scans, we selected the scan closest to transplant. All 
scans were noncontrast. We excluded patients who received a 
simultaneous pancreas or liver transplant. Typical postkidney 
transplant immunosuppression regimens included tacrolimus, 
which switched to cyclosporine if post- transplant glucose intol-
erance developed. All patients typically received methylpredni-
solone for 4 days post- transplant, without further maintenance 
steroids unless the patient was immunologically higher risk. 
Patients with delayed graft function generally remained on 
steroids.
2.2 | Analytic morphomics
CT scans were processed using semi- automated algorithms pro-
grammed into MATLAB v13.0 (MathWorks; Natick, MA, USA). As 
described in our previous work,10-12 total psoas, psoas muscle den-
sity, and aortic wall calcification were measured after identifying 
individual vertebral levels on each patient’s CT scan. Briefly, total 
psoas area was measured as the cross- sectional areas of the left 
and right psoas muscles at the level of L4. Using automated method, 
each pixel within the area encompassed was sampled for its radio-
logic density (in Hounsfield Units [HU]). Aortic calcification was 
measured as a percentage of the aortic wall surface area from L1 to 
L3. These measurements are shown in Figure 1. As previously de-
scribed,13,14 morphometric age was computed as a function of the 
morphometric characteristics (psoas area, density, and aortic calcifi-
cation) of a control population—namely potential kidney donors and 
F IGURE  1  (A) Using semi- automated algorithms, the psoas muscles were outlined and total psoas area (TPA), and psoas density were 
determined. (B) Abdominal aortic calcification was measured on the wall of the infrarenal aorta from L1 to L3. After determining the centerline 
and radius, calcification was identified based on a relative threshold from the aortic lumen and expressed as a percentage of the total wall 
area. Below, these findings are further visualized in a two- dimensional mapping of the selected aortic wall. Individual pixels can be assessed for 
calcification severity by measuring the thickness of calcification (not utilized in this study)
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randomly selected trauma patients. The algorithm developed from 
this standardized population was applied to the study population to 
determine each patient’s morphometric age.
2.3 | Clinical data
Clinical data were retrospectively collected from the electronic 
medical record at UHCMC. Data were de- identified, encoded, and 
sent to UMMS to be merged with the de- identified and coded mor-
phomic data. Clinical variables collected included: age, sex, race, 
body mass index (BMI), chronic kidney disease (CKD) etiology 
(hypertension, diabetes mellitus, autoimmune, or other), hepatitis 
C (HCV) viral infection, waitlist duration, dialysis vintage pretrans-
plant, prior kidney transplant, deceased donor, expanded criteria 
donor (ECD) status, donor age, prednisone post- transplant, cal-
cineurin inhibitor use post- transplant, primary nonfunction, and 
delayed graft function.
2.4 | Statistical analysis
Descriptive statistics were computed for the study population. 
Continuous variables were summarized by mean and standard devia-
tion, and frequency tables were produced for categorical variables. 
The Pearson product moment correlation, r, was used to assess col-
linearity between the two age metrics. Kaplan- Meier analysis was 
performed to stratify survival based on tertiles of chronologic and 
morphometric age. Standard survival analysis using Cox regression 
was performed to determine the covariate- adjusted effect of mor-
phometric age on post- transplantation mortality. Patients began 
follow- up at the time of transplantation and continued until the ear-
liest of death or loss to follow- up. Adjustment covariates include all 
variables listed above. All available covariates were initially evaluated 
univariately, and those with P < .20 were entered into the multivari-
ate model.16,17 A final subset of adjustment criteria was determined 
using backwards selection. All analyses were performed using STATA 
TABLE  1 Patient demographic and clinical data
Chronologic age tertile
Youngest (19.4- 49.7 y) Middle (49.7- 61.2 y) Oldest (61.2- 74.7 y) All patients
N 52 53 53 158
Male 67.3% (35) 75.5% (40) 62.3% (33) 68.4% (108)
Chronologic age, years 39.4 ± 8.4 55.7 ± 3.4 66.6 ± 4.2 54 ± 12.5
Morphometric age 53.9 ± 7.9 61.6 ± 12.1 68.7 ± 14.8 61.4 ± 13.3
(Range) (35.2- 73.4) (40.2- 91.4) (45.8- 107.7)
African- American race 23.1% (12) 43.4% (23) 26.4% (14) 31.0% (49)
BMI, kg/m2 28.1 ± 6.4 28.7 ± 6 29.4 ± 5.5 28.7 ± 6
TPA, mm2 2510.7 ± 785.7 2603.3 ± 858.8 2159 ± 696.3 2423.8 ± 801.5
Psoas density, HU 45.2 ± 7.6 41.9 ± 8.7 38.5 ± 8.6 41.8 ± 8.7
Percent wall calcification 3.4 ± 6.5 13.3 ± 15.7 19.3 ± 21.1 12 ± 16.9
Waitlist duration, years 2.2 ± 2.4 2.7 ± 2.4 2.3 ± 1.8 2.4 ± 2.2
ESRD etiology: hypertension 9.6% (5) 26.4% (14) 34.0% (18) 23.4% (37)
ESRD etiology: diabetes mellitus 34.6% (18) 34.0% (18) 28.3% (15) 32.3% (51)
ESRD etiology: autoimmune 9.6% (5) 9.4% (5) 5.7% (3) 8.2% (13)
ESRD etiology: other 46.2% (24) 30.2% (16) 32.1% (17) 36.1% (57)
Pretransplant dialysis 76.9% (40) 81.1% (43) 81.1% (43) 79.7% (126)
Duration of pretransplant dialysis, in years 2.6 ± 2.7 3.2 ± 2.8 2.4 ± 2.2 2.7 ± 2.6
Deceased donor 55.8% (29) 67.9% (36) 60.4% (32) 61.4% (97)
Expanded criteria donor 3.8% (2) 15.1% (8) 28.3% (15) 15.8% (25)
Living- related donor 25.0% (13) 24.5% (13) 24.5% (13) 24.7% (39)
Living- unrelated donor 19.2% (10) 7.5% (4) 15.1% (8) 13.9% (22)
Donor age, years 39.9 ± 13 43.6 ± 13.6 50.2 ± 11.3 44.6 ± 13.3
Prior transplant 21.2% (11) 11.3% (6) 5.7% (3) 12.7% (20)
HCV positivity 5.8% (3) 13.2% (7) 1.9% (1) 7.0% (11)
Cyclosporine use 11.5% (6) 1.9% (1) 1.9% (1) 5.1% (8)
Steroids beyond postoperative day 4 71.2% (37) 54.7% (29) 47.2% (25) 57.6% (91)
Primary nonfunction 0% (0) 1.9% (1) 3.8% (2) 1.9% (3)
Delayed graft function 7.7% (4) 9.4% (5) 15.1% (8) 10.8% (17)
Continuous variables presented as mean ± SD.
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v14.0 (College Station, TX, USA). A two- sided significance of P < .05 
was used for all analyses.
3  | RESULTS
3.1 | Study population
Overall, 158 adult patients who underwent kidney transplantation 
received a 1- year preoperative CT scan, which included the regions 
of interest for morphometric assessment. These patients served as 
the study cohort. Demographics of the study population are shown 
in Table 1, stratified by tertiles of chronologic age. The mean chrono-
logic age at transplant was 54.0 ± 12.5 years, and the mean morpho-
metric age was 61.4 ± 13.3. Overall, 66.5% (n = 105) of patients had 
a morphometric age greater than their chronologic age. Deceased- 
donor kidneys were utilized in 61.4% (n = 97) of cases, and living 
related donors for 24.7% (n = 39). Overall, expanded criteria donors 
(ECD) accounted for 15.8% (n = 25).
Further analysis shows that there is a positive correlation between 
chronologic and morphometric age, with r = .49. This correlation de-
creased as older patients are compared. Among the tertile of youngest 
chronologic age, r = .34; among the middle tertile, r = .26; among the 
oldest tertile of chronologic age, r = .15.
3.2 | Graft survival
Death- censored graft loss was observed in 10.8% (17) of patients. At 
1 year after transplant, death- censored graft loss was seen in 1.9% 
(3) of patients. At 5 years, death- censored graft loss was seen in 7.6% 
(12) of patients. While these patients were both chronologically older 
(56.1 vs 53.7 years, P = .55) and morphometrically older (66.4 vs 
60.8 years, P = .13) than those who did not experience graft loss, the 
differences were not significant when age was utilized as a continuous 
variable. When patients are stratified into tertiles of chronologic and 
morphometric age, the differences in graft loss among the tertiles also 
were not significant (P = .72 and P = .92, respectively).
Overall uncensored graft loss was observed in 28.5% (n = 45) of 
patients, with 6.3% (10) occurring at 1 year and 20.3% (32) occurring 
at 5 years. When patients are stratified into tertiles of age, the differ-
ences in five- year uncensored graft loss were not significantly differ-
ent (P = .16) among the chronologic age tertiles, but were significantly 
different among morphometric age tertiles (P = .008).
3.3 | Patient survival
Overall patient survival at 1 year, 3 years, and 5 years was 93.7% 
(148/158), 86.2% (112/130), and 74.2% (66/89), respectively. Cardiac 
etiologies were the most common cause of death, representing 50% 
of deaths at 1 year and 43.5% at 5 years. The remaining causes of 
death at 1 year were infections (30%) and malignancy (10%), with 
10% of deaths unspecified. The remaining causes of death at 5 years 
were infections (17.4%), malignancy (8.7%), trauma (4.3%), and suicide 
(4.3%), with 21.7% of deaths unspecified.
Figure 2 shows Kaplan- Meier survival stratified by tertiles of 
chronologic age and morphometric age, respectively. In comparing 
tertiles of chronologic age, the youngest patients had much greater 
survival compared to the middle and oldest patients, as would be ex-
pected. Similarly, when comparing the tertiles of morphometric age, 
younger and middle age patients had much greater survival compared 
to the morphometric oldest patients. When the chronologically oldest 
patients are stratified by tertiles of morphometric age, as shown in 
Figure 3, the morphometric young and middle age tertiles had greater 
survival rates compared to the oldest. A similar finding was observed 
for the chronologic middle- aged tertile, while the chronologic young-
est tertile did not show significant differences when stratified by mor-
phometric age.
F IGURE  2 Kaplan- Meier survival curves were determined for the 
study population, stratified by both tertiles of chronologic age (A) and 
morphometric age (B)
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Cox regression was used to determine whether morphometric 
age is a significant independent predictor of survival. Morphometric 
age was utilized as a continuous variable in the model, as was chrono-
logic age. All available covariates were initially evaluated univariately, 
and those with P < .20 were entered into the multivariate model. 
These  results are summarized in Table 2. The final subset of adjust-
ment  covariates was chosen by backwards selection, which is sum-
marized in Table 3. The model showed that morphometric age is a 
significant independent predictor (hazard ratio [HR] = 1.06 per mor-
phometric year, 95%CI: 1.03- 1.08; P < .001), as were diabetes mel-
litus (HR = 3.76, 95%CI: 1.58- 8.94; P = .003), waitlist time (HR = 1.19 
per year, 95%CI: 1.02- 1.39; P = .024), and delayed graft function 
(HR = 2.72, 95%CI: 1.08- 6.84; P = 0.034). Chronological age was not 
a significant covariate (HR = 1.03 per year, 95%CI: 0.98- 1.07; P = .22). 
All other covariates utilized in survival analysis were not significant 
and were excluded in the final modeling. Figure 4 utilizes the final sub-
set of adjustment covariates to determine the adjusted survival rates 
for each tertile of chronologic age, further stratified by morphometric 
age. Using the 50th percentile of morphometric age and chronologic 
age, the hazard ratio can be determined for any age value. For exam-
ple, the hazard ratio for a patient whose morphometric age is the 75th 
percentile has a 10% greater post- transplantation mortality rate than 
a patient with a morphometric age at the 50th percentile, covariate 
adjusted. Likewise, a patient with chronologic age at the 75th percen-
tile has a 6% greater covariate- adjusted mortality rate compared to 
patients aged at the 50th percentile.
F IGURE  3 Kaplan- Meier survival curves were stratified by morphometric age for each tertile of chronologic age. The youngest chronologic 
tertile (3A) includes patients with age at transplant of 19- 49. The middle chronologic tertile (3B) includes patients with ages 49- 61. The oldest 
chronologic tertile (3c) includes patients with ages 61- 74
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4  | DISCUSSION
We have demonstrated a novel approach to quantifying frailty as 
an indicator of outcomes in patients undergoing kidney transplan-
tation. By utilizing cross- sectional imaging, we assigned a mor-
phometric age to recipients to objectively assess mortality risk 
following transplantation. Our data suggest that morphometric age 
is a significant predictor of patient survival independent of chrono-
logic age and comorbidity. Furthermore, among the chronologically 
oldest patients, those with a younger morphometric age showed in-
creased survival compared to the patients who with older morpho-
metric age. These results demonstrate that analytic morphomics 
may serve as a more objective “eyeball test” of the level of patient 
frailty and physiological reserve in regard to fitness for kidney 
transplantation.
There is a growing body of literature that has investigated 
novel methods of preoperative risk stratification. The measure of 
frailty has been strongly associated with postsurgical outcomes, 
including mortality after kidney transplantation.2,9 Other studies 
have also demonstrated that sarcopenia offers a poorer progno-
sis compared to patients with relatively preserved muscle mass,18 
even for patients only receiving conservative therapy.19 These 
studies often focus on indirect measures of muscle mass, such as 
handgrip strength or bioelectric impedance. Our study differs in 
that we directly measure trunk muscle size, muscle density, and 
vascular calcification to generate an intuitive calculation of risk, 
namely morphometric age. Additionally, our study suggests that 
morphometric age offers improved survival stratification compared 
to chronologic age.
This study suggests the potential for analytic morphomics to be 
informative for both clinicians and patients. Most importantly, the ap-
plication to transplantation may help discriminate patients most likely 
to survive following transplantation, especially older patients. It is not 
uncommon in clinical parlance to describe a patient as appearing older 
or younger than stated age. While we observed collinearity between 
morphometric and chronologic age, this correlation decreases for 
the oldest patients, suggesting morphometric age can be viewed as 
a unique domain of risk assessment and serve as a proxy for the afore-
mentioned clinical judgment. While older age was once thought to be 
a necessary preclusion, kidney transplantation has increasingly be-
come a viable option for select older patients.20,21 Still, older patients 
are not accepted for transplantation to the same extent as younger 
patients, and there remain many unique challenges to transplantation 
in older adults.22-24 Morphometric age has the potential to improve 
this selection process and provide transplant surgeons more objec-
tive measures to assess and compare prospective survival benefits. 
Furthermore, there is a readiness to implement these strategies given 
that preoperative imaging has become more prevalent for transplant 
candidates.
TABLE  2 Univariate survival analysis
Covariate
Hazard ratio 
(95%CI) P value
Morphometric age (per morpho-
metric year)
1.07 (1.04- 1.09) <.001
ESRD: diabetes mellitus 4.83 (2.08- 11.20) <.001
Delayed graft function 5.97 (2.52- 14.12) <.001
Waitlist time (per year) 1.22 (1.08- 1.38) .001
Chronologic age (per year) 1.05 (1.02- 1.09) .003
Deceased donor 3.07 (1.36- 6.92) .007
Dialysis 9.52 (1.30- 69.81) .027
ECD 2.47 (1.03- 5.91) .043
ESRD: other 0.49 (0.22- 1.09) .078
Male gender 1.69 (0.75- 3.81) .20
Prior transplant 0.41 (0.10- 1.72) .22
Donor age 1.02 (0.99- 1.05) .26
ESRD: autoimmune 0.32 (0.04- 2.34) .26
BMI 1.03 (0.97- 1.09) .32
HCV positivity 0.50 (0.12- 2.13) .35
ESRD: HTN 1.39 (0.68- 2.83) .36
African- American race 1.15 (0.56- 2.40) .70
TABLE  3 Results of survival analysis using Cox regression
Covariate
Hazard Ratio 
(95%CI) P value
Morphometric age* (per 
morphometric year)
1.06 (1.03- 1.08) <.001
ESRD: diabetes mellitus* 3.76 (1.58- 8.94) .003
Waitlist time* (per year) 1.19 (1.02- 1.39) .024
Delayed graft function* 2.72 (1.08- 6.84) .034
Dialysis 3.86 (0.51- 29.94) .19
Chronologic age (per year) 1.03 (0.98- 1.07) .22
Deceased donor 1.46 (0.55- 3.90) .45
ESRD: other 0.57 (0.07- 4.57) .60
ECD 1.23 (0.48- 3.18) .67
*Indicates selection to final model.
F IGURE  4 Covariate- adjusted hazard ratio for mortality was 
determined after selecting a subset of covariates. The reference 
age (HR = 1) was the 50th percentile for each metric (56.3 y for 
chronologic age; 58.3 for morphometric age)
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There are several important limitations of this work that must be 
taken into consideration. First, it is a retrospective study at a single in-
stitution with a relatively small cohort of patients—as such, it demon-
strates an association, rather than causative relationship, between 
morphometric age and survival. Future studies should aim to include 
a larger sample size across multiple transplant centers, and additional 
work is needed to validate morphometric age in other populations. 
Second, patients were included in the study only if they received a pre-
operative abdominal CT scan within 1 year of transplant. It is conceiv-
able that an individual patient’s morphometric measures can change 
significantly within the course of a year, especially those with ESRD, 
or that the selection bias inherent in the clinical protocol indications 
for CT scanning could influence the results. Furthermore, the selection 
bias inherent in the clinical protocol indications for CT scanning could 
influence the results, as those who received CT scans—that is, those 
who were older or diabetic—are enriching the cohort with higher risk 
patients. Additionally, given the limitations of a retrospective study, we 
do not have a comprehensive set of patient comorbidities. Finally, our 
methodology used to determine morphometric age is based upon only 
three morphometric measures taken from predetermined living kidney 
donor and trauma patients, as these patients are intuitively the most 
morphometrically close to their chronological age. However, the use 
of this morphometric standard for comparison may not be appropriate 
for ESRD patients, particularly as we did not examine patients who 
were not eventually transplanted. Thus, our study is only applicable to 
ESRD patients undergoing transplantation and its implications cannot 
be extended to waitlist survival. Furthermore, many other methodol-
ogies and measurements could potentially inform morphometric age. 
Frailty may be suitable in this regard; however, no meaningful mea-
sures of frailty were apparent in the available patient records.
5  | CONCLUSIONS
Morphometric age is an independent predictor of patient survival 
following kidney transplantation. As patients continue to present 
with ESRD at older ages, additional work is warranted to assess and 
validate novel measures that help inform fitness for kidney trans-
plantation. Future studies can aim to identify other morphomic 
factors that elucidate the complex relationship between age and 
physiologic reserve in the transplant candidate. It is also feasible 
that analytic morphomics may predict outcomes for ESRD patients 
who do not undergo transplantation. The potential of analytic mor-
phomics to identify higher risk patients may also allow for inter-
vention therapies to be implemented and improvements in organ 
allocation. Overall, it is conceivable that cross- sectional imaging 
studies will become a routine component of the standard transplant 
risk assessment for appropriate patients. For those centers already 
obtaining such scans, or for those patients who already have such 
imaging, morphomic assessment is easily extractable from most ap-
propriately targeted CT scans with minimal- to- no additional cost, 
allowing more complete utilization of a test that has already been 
obtained.
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